Top Story Today
Hepatitis B Just Got Its First Real Shot at a Cure in Three Decades
For 30 years, chronic hepatitis B treatment meant one thing: pills forever. GSK and Ionis just shattered that with positive Phase 3 data for bepirovirsen, a six-month therapy that achieved statistically significant "functional cure" rates across two massive trials enrolling 1,800+ patients. Instead of merely suppressing the virus, the drug shreds its RNA, strips its immune-evading protein shield, and wakes up the body's own defenses to finish the job. With regulatory filings already underway and FDA Fast Track designation in hand, GSK is projecting blockbuster-scale commercial potential.
Why it matters: Fewer than 3% of the 254 million people with chronic hepatitis B currently receive treatment, largely because existing drugs demand lifelong adherence. A finite, six-month cure wouldn't just be a medical milestone; it would fundamentally reshape the global public health calculus for one of the world's deadliest infectious diseases.
Read more →Clinical Setbacks
Kyowa Kirin Kills Its Most Promising Eczema Drug After Cancer Cases Surface
Amgen ended its collaboration on rocatinlimab for strategic portfolio reasons, returning full rights to the OX40-targeting eczema drug to Kyowa Kirin, which confirmed trial continuity and planned FDA filing. The biological logic behind the OX40 pathway remains uncomfortable: OX40 helps your immune system hunt cancer cells, so blocking it may have disabled the body's own tumor surveillance. The fallout extends beyond one drug, raising scrutiny over 10+ OX40-pathway therapies in development across the industry.
Read more →Deals and Financing
Teva Locks In $400M From Blackstone Without Selling a Single Share
Teva just pulled off the biotech financing equivalent of paying your contractor with future rental income. Blackstone Life Sciences will provide $400 million over four years to fund Phase 3 trials of duvakitug, a promising IBD drug co-developed with Sanofi. In return, Blackstone gets milestones and low single-digit royalties on a drug Teva management says could hit $2 to $5 billion in peak annual sales. Zero dilution, no new debt; just a clever bet on royalty financing's rising moment.
Read more →Science and Discovery
A Stealth Startup Wants to Turn Cancer's Deadliest Weapon on Autoimmune Disease
Prolium Bioscience emerged from stealth with $50 million from RTW Investments and a wild thesis: T-cell engagers, the bispecific antibodies built to obliterate cancer cells, might also cure severe autoimmune conditions. Their lead drug, PRO-203, is a CD20xCD3 antibody already dosing healthy volunteers, with a Phase 1/2 trial in systemic sclerosis reportedly expected by Q2 2026. The big question is whether a weapon designed for cancer can be made gentle enough for patients who aren't terminal.
Read more →A Clinical Trial Tech Company Just Started Testing Its Own Asthma Drug
Vial Health Technology, a company best known for digitizing clinical trials, dosed its first patient with a bispecific antibody targeting both IL-13 and TSLP in asthma. The dual-target approach could address gaps left by Dupixent and Tezspire, with preclinical data showing superior potency and a potential dosing schedule of just two to four injections per year. Interim Phase 1 data is expected in the first half of 2026.
Read more →